Trial Profile
MULTICENTRE, OPEN LABEL, RANDOMIZED, TWO-ARM, PARALLEL-GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF ENVARSUS COMPARED WITH TACROLIMUS USED AS PER CURRENT CLINICAL PRACTICE IN THE INITIAL MAINTENANCE SETTING IN DE NOVO KIDNEY TRANSPLANT PATIENTS.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary) ; Tacrolimus; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms STEADY study
- Sponsors Chiesi Farmaceutici
- 06 Jun 2018 Primary endpoint has been met. (Tacrolimus total daily dose (TDD)) as per result presented at the 2018 American Transplant Congress
- 06 Jun 2018 Results presented at the 2018 American Transplant Congress
- 10 Mar 2017 This trial has been completed in Austria - (end date: 2017-01-24).